From the Research
Dalteparin (Fragmin) is not the recommended treatment for chronic venous insufficiency (CVI), instead, Daflon 500 mg is a more effective and well-tolerated option. The provided evidence does not support the use of dalteparin in CVI, and the most recent and highest quality study 1 suggests that Daflon 500 mg is a well-established and well-tolerated treatment option for patients with CVI. Some key points to consider when using Daflon 500 mg for CVI include:
- It is typically prescribed as 500 mg tablets taken twice daily
- It contains micronized purified flavonoid fraction (MPFF), which helps improve venous tone and lymphatic drainage
- It reduces inflammation in blood vessel walls and decreases capillary permeability, leading to improved blood flow in the veins and reduced symptoms like leg heaviness, pain, and swelling
- Patients should take Daflon 500 mg consistently for at least 2-3 months to see maximum benefit, and it can be used long-term for chronic venous insufficiency
- While using Daflon 500 mg, patients should also implement lifestyle changes like regular exercise, elevating legs when resting, and wearing compression stockings for optimal results
- Daflon 500 mg is generally well-tolerated, with mild gastrointestinal side effects being the most common, and it's safe for most patients, including pregnant women, but those with specific health conditions should consult their doctor before use.